Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innocoll's CollaGUARD dressing:

This article was originally published in Clinica

Executive Summary

Innocoll has received its first regulatory approval in the US, after its wholly-owned subsidiary, Innocoll Pharmaceuticals, gained 510k clearance for its advanced wound care product, CollaGUARD. The collagen-based dressing, which incorporates the firm's CollaRx membrane technology, can be used to manage superficial and deep wounds. The worldwide market for advanced wound care dressings is worth well over $1bn, the Ashburn, Virginia firm said, adding that because CollaGUARD can be manufactured using a "highly efficient and cost-effective process", it can compete "very favourably" against other collagen-based wound care products. CollaGUARD is already approved in Europe. Follow-up products currently in development include a silver-impregnated version of CollaGUARD for infected wounds or wounds at risk of infection, and DermaSIL, a collagen-synthetic foam composite dressing for deep and heavily exuding wounds.

You may also be interested in...



Executives On The Move: CEOs Named At Elevation Oncology, PainReform Ltd

Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma

Viatris Kickstarts Business With Tentative Approval For Pediatric Dolutegravir

The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program. 

J&J Leverages Power Of Digital Personalization With Nicorette UK Extension

Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel